• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Breakthrough Increases Efficacy of B-Cell Lymphoid Malignancy Treatment

Article

Ibrutinib, an FDA approved treatment with generally high response rates, can be resisted by some patients.

Researchers have found a solution to resistance acquired by some users of ibrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor used to treat patients with B-cell lymphoid malignancies.

According to a recent study published in Cell Death & Disease, an increase of the tumor suppressing genes FOXO3a and Phosphatase and tensin homolog (PTEN) in the nucleus of affected cells lowers resistance to BTK inhibition.

“Our data revealed for the first-time increased expression of phosphorylated and cytoplasmic FOXO3a in ibrutinib-resistant (IB-R) cells,” authors said.

BTK is responsible for mediating B-cell receptor signaling. Chronically overreactive BTK can result in B-cell lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Along with BTK, protein kinase B (AKT) assists in transferring signals within cells and can act as a drug resistant mechanism.

Ibrutinib, an FDA approved treatment with generally high response rates, can be resisted by some patients. According to researchers, up to 5% of patients receiving ibrutinib experience more aggressive activated B-cell (ABC)-DLBCL and up to one-third of these patients develop a relapse of the disease. These numbers prompted researchers to conduct a further investigation into this risk.

Researchers first generated IB-R cells, such as CLL and ABC-DLBCL cells, and exposed them to the drug to better understand the cells’ resistance mechanisms. By conducting a series of different tests, comparing resistant cells with non-resistant cells, researchers observed downregulation of FOXO3a and PTEN levels and a higher activation of AKT in IB-R cells.

When researchers inhibited AKT and restored levels of FOXO3a in IB-R cells they found increased ibrutinib induced apoptosis, or cell death, “demonstrating the importance of these cell survival factors for ibrutinib-resistance.”

In particular, 1 exportin inhibitor, selinexor, worked with the ibrutinib present in IB-R cells to restore FOXO3a and PTEN in affected nuclei, facilitating the intended use of the drug.

“The FOXO3a/PTEN/AKT-axis emerges as a critical determinant of acquired IB-R in CLL and DLBCL. Reduced Nuclear FOXO3a downregulates PTEN…and promotes pro-survival AKT activation in IB-R cells,” researchers said. For future treatments, they recommend a combination of selinexor and ibrutinib as a strategy to sensitize IB-R cells.

Reference

Kapoor I, Li Y, Sharma A, et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 2019;10(12):924. doi: 10.1038/s41419-019-2158-0.

Related Videos
Amitkumar Mehta, MD, MBA
Alma Habib, MD
Jennifer Vaughn, MD, The Ohio State University Comprehensive Cancer Center
Sarah Wall, MD
Adam Kittai MD
Fabian Lang, MD, Goethe Hospital, Germany
Wojciech Jurczak, MD, PhD
Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany
Dr Fabian Lang of Goethe University Hospital in Frankfurt, Germany
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.